Search Results - "Cowey, C. Lance"

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials by Schadendorf, Dirk, Wolchok, Jedd D, Hodi, F Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C Lance, Lao, Christopher D, Chesney, Jason, Robert, Caroline, Grossmann, Kenneth, McDermott, David, Walker, Dana, Bhore, Rafia, Larkin, James, Postow, Michael A

“…Purpose Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because…”
Get full text

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma by Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C. Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier F, Smylie, Michael, Hogg, David, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bastholt, Lars, Rizzo, Jasmine I, Balogh, Agnes, Moshyk, Andriy, Hodi, F. Stephen, Wolchok, Jedd D

“…With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of nivolumab plus ipilimumab, as…”
Get full text

Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA by Cowey, C Lance, Mahnke, Lisa, Espirito, Janet, Helwig, Christoph, Oksen, Dina, Bharmal, Murtuza

“…This retrospective study of patients in the USA with metastatic Merkel cell carcinoma (mMCC) aimed to assess patient responses to second-line and later (2L+)…”
Get full text

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma by Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D, Wagstaff, John, Schadendorf, Dirk, Ferrucci, Pier F, Smylie, Michael, Dummer, Reinhard, Hill, Andrew, Hogg, David, Haanen, John, Carlino, Matteo S, Bechter, Oliver, Maio, Michele, Marquez-Rodas, Ivan, Guidoboni, Massimo, McArthur, Grant, Lebbé, Celeste, Ascierto, Paolo A, Long, Georgina V, Cebon, Jonathan, Sosman, Jeffrey, Postow, Michael A, Callahan, Margaret K, Walker, Dana, Rollin, Linda, Bhore, Rafia, Hodi, F. Stephen, Larkin, James

“…Both nivolumab alone and nivolumab plus ipilimumab resulted in longer overall survival among patients with previously untreated advanced melanoma than…”
Get full text

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma by Weber, Jeffrey, Mandala, Mario, Del Vecchio, Michele, Gogas, Helen J, Arance, Ana M, Cowey, C. Lance, Dalle, Stéphane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus O, Middleton, Mark R, Maio, Michele, Atkinson, Victoria, Queirolo, Paola, Gonzalez, Rene, Kudchadkar, Ragini R, Smylie, Michael, Meyer, Nicolas, Mortier, Laurent, Atkins, Michael B, Long, Georgina V, Bhatia, Shailender, Lebbé, Celeste, Rutkowski, Piotr, Yokota, Kenji, Yamazaki, Naoya, Kim, Tae M, de Pril, Veerle, Sabater, Javier, Qureshi, Anila, Larkin, James, Ascierto, Paolo A

“…In a randomized trial involving more than 900 patients undergoing resection of advanced melanoma, adjuvant nivolumab was associated with a higher rate of…”
Get full text

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma by Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D, Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier F, Hill, Andrew, Wagstaff, John, Carlino, Matteo S, Haanen, John B, Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A, Ascierto, Paolo A, Long, Georgina V, Callahan, Margaret K, Postow, Michael A, Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M, Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D

“…The addition of nivolumab (anti–PD-1) to ipilimumab (anti–CTLA-4) did not further improve response rate or progression-free survival among patients with…”
Get full text

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib by Robinson, Sara D, O'Shaughnessy, Joyce A, Lance Cowey, C, Konduri, Kartik

“…Highlights • Somatic BRAF mutations have been reported in 1–4% of non-small cell lung cancers. • Our patient had NSCLC with metastases to her brain with the…”
Get full text

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF -Mutant Melanoma by Hamid, Omid, Cowey, C Lance, Offner, Michelle, Faries, Mark, Carvajal, Richard D

“…No head-to-head studies exist comparing BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) combination treatments for mutant melanoma. A side-by-side analysis of…”
Get full text

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma by LANCE COWEY, C, AMIN, Chirag, MOORE, Dominic T, KIM, William Y, GODLEY, Paul A, WHANG, Young E, FIELDING, Julia R, KIMRYN RATHMELL, W, PRUTHI, Raj S, WALLEN, Eric M, NIELSEN, Matthew E, GRIGSON, Gayle, WATKINS, Cathy, NANCE, Keith V, CRANE, Jeffrey, JALKUT, Mark

“…The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of…”
Get full text

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy by Cowey, C. Lance, Robert, Nicholas J., Espirito, Janet L., Davies, Kalatu, Frytak, Jennifer, Lowy, Israel, Fury, Matthew G.

“…Prior studies of conventional chemotherapy or epidermal growth factor receptor inhibitors for advanced (ie, locally advanced cutaneous squamous cell carcinoma…”
Get full text

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics by Ribas, Antoni, Zhang, Weijiang, Chang, Ilsung, Shirai, Keisuke, Ernstoff, Marc S., Daud, Adil, Cowey, C. Lance, Daniels, Gregory, Seja, Elizabeth, O'Laco, Elizabeth, Glaspy, John A., Chmielowski, Bartosz, Hill, Todd, Joe, Andrew K., Grippo, Joseph F.

“…Vemurafenib is an orally bioavailable BRAF inhibitor approved for the treatment of BRAFV600‐mutant metastatic melanoma. It is important to understand the…”
Get full text

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival by Mandalá, Mario, Larkin, James, Ascierto, Paolo A, Del Vecchio, Michele, Gogas, Helen, Cowey, C Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey

“…BackgroundSeveral therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to…”
Get full text

HIF1α and HIF2α exert distinct nutrient preferences in renal cells by Arreola, Alexandra, Cowey, C Lance, Coloff, Jonathan L, Rathmell, Jeffrey C, Rathmell, W Kimryn

“…Hypoxia Inducible Factors (HIF1α and HIF2α) are commonly stabilized and play key roles related to cell growth and metabolic programming in clear cell renal…”
Get full text

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma by Cowey, C Lance

“…Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI). Among other VEGF TKIs, tivozanib stands apart due to its…”
Get full text

Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community by Sonpavde, Guru, Watson, Deidre, Tourtellott, Marcia, Cowey, C. Lance, Hellerstedt, Beth, Hutson, Thomas E, Zhan, Feng, Vogelzang, Nicholas J

“…Micro-Abstract Because the frequency of first-line cisplatin-based chemotherapy administration in patients with advanced urothelial carcinoma is unknown, a…”
Get full text

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma by Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Butler, Marcus O, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John B A G, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bas, Tuba, Ritchings, Corey, Larkin, James, Hodi, F Stephen

“…In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus…”
Get full text

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial by Ascierto, Paolo A, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M, Dalle, Stephane, Cowey, C Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O, Maio, Michele, Middleton, Mark R, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A, Millward, Michael, Khushalani, Nikhil I, Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James, Weber, Jeffrey

“…Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant…”
Get full text

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy by Cowey, C. Lance, Rathmell, W. Kimryn

Get full text

The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multitargeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response by Cowey, C. Lance, Fielding, Julia R, Kimryn Rathmell, W

“…Objectives To characterize radiographic intratumoral contrast enhancement in the primary tumor of patients with renal cell carcinoma treated with either…”
Get full text

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study by Weber, Jeffrey S, Carlino, Matteo S, Khattak, Adnan, Meniawy, Tarek, Ansstas, George, Taylor, Matthew H, Kim, Kevin B, McKean, Meredith, Long, Georgina V, Sullivan, Ryan J, Faries, Mark, Tran, Thuy T, Cowey, C Lance, Pecora, Andrew, Shaheen, Montaser, Segar, Jennifer, Medina, Theresa, Atkinson, Victoria, Gibney, Geoffrey T, Luke, Jason J, Thomas, Sajeve, Buchbinder, Elizabeth I, Healy, Jane A, Huang, Mo, Morrissey, Manju, Feldman, Igor, Sehgal, Vasudha, Robert-Tissot, Celine, Hou, Peijie, Zhu, Lili, Brown, Michelle, Aanur, Praveen, Meehan, Robert S, Zaks, Tal

“…Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected melanoma, but many patients recur. Our study aimed to evaluate whether…”
Get full text